Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
Holding ZYME?
Track your performance easily
ZYME Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.02 - $13.27
Previous Close$12.42
Volume283.61K
Average Volume (3M)727.07K
Market Cap
$889.50M
Enterprise Value$579.38M
Total Cash (Recent Filing)$330.15M
Total Debt (Recent Filing)$20.03M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 05, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding71,047,390
10 Day Avg. Volume735,247
30 Day Avg. Volume727,065
Standard Deviation0.16
R-Squared0.14
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.22
Price to Sales (P/S)14.07
Price to Cash Flow (P/CF)-8.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.24
Enterprise Value/Gross Profit7.62
Enterprise Value/Ebitda-5.72
Forecast
1Y Price Target
$13.75Price Target Upside10.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Zymeworks News
PremiumCompany Announcements
Zymeworks to Showcase Innovations at Investor Conferences
PremiumCompany Announcements
Zymeworks Secures FDA Approval for Ziihera
PremiumCompany Announcements
Zymeworks Launches Phase 1 Trial for ZW191
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPhase 2 results of zanidatamab combination therapy in HER2+ GEA cancer patients showed an 84% overall response rate with a median duration of response of 18.7 months.
FDA ApprovalPotential FDA approval of zanidatamab in second-line bile tract cancer is noted as a value inflection point.
Preclinical ResultsZymeworks will present preclinical results for two of its preclinical ADC assets, ZW220 and ZW251, at the upcoming EORTC-NCI-AACR meeting.
Bears Say
Development DiscontinuationThe difference in net loss is driven by a non-cash impairment charge of $17.3M as a result of the decision to discontinue the development of zanidatamab zovodotin.
Efficacy ConcernsLower doses of Enhertu required for combination with chemo and Keytruda in gastric cancer may raise concerns about efficacy at reduced dosage.
Financial PerformanceZymeworks recorded a net loss of $0.49 per share—wider than the previously forecast net loss of $0.36 per share.
---
Ownership Overview
11.65% Insiders
752.96% Mutual Funds
6062.97% Other Institutional Investors
1756.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $6.01 and its highest was $13.27 in the past 12 months.
What is Zymeworks Inc’s market cap?
Currently, no data Available
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Nov 05, 2024 which is 36 days ago.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Aug 01, 2024. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.417 by -$0.073.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is -$0.4.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 71,047,390 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.417. Following the earnings report the stock price went up 0.89%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Among the largest hedge funds holding Zymeworks Inc’s share is Perceptive Advisors LLC. It holds Zymeworks Inc’s shares valued at 14M.
---
Zymeworks Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.75 (10.71% Upside)
$13.75 (10.71% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 611.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.67%
12-Months-Change
Fundamentals
Return on Equity
-26.32%
Trailing 12-Months
Asset Growth
-14.35%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
---
ZYME Company Deck
---
ZYME Earnings Call
Q2 2024
0:00 / 0:00
---
ZYME Stock 12 Month Forecast
Average Price Target
$13.75
▲(10.71% Upside)
Technical Analysis
Best Analysts Covering ZYME
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+42.64%
reiterated a buy rating 7 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +42.64% per trade.
---